



Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

November 9, 2017

MALVERN, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced with great sorrow that Rick Bierly, a valued member of the company's board of directors and chairman of the audit committee of the board, has passed away.

"Rick was a highly appreciated board member with comprehensive medical and business experience, and we are deeply saddened by his passing. He was an inspiring leader and friend. He brought great value and warmth to our company and he will be greatly missed," said Aclaris' President and CEO Dr. Neal Walker.

"Rick was appointed to Aclaris Therapeutics' board of directors on October 2015, and he made valuable contributions to the Board during his tenure. Our thoughts are with Rick's family."

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.

Contact:

Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclariastx.com

Source: Aclaris Therapeutics, Inc.